Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination

Yoshiyuki Fujiwara, Toshiro Nishida, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Kazuyoshi Yamamoto, Jeong Ho Moon, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Gastric cancer with cancer cells on peritoneal cytology has very poor prognosis because of the existence of simultaneous peritoneal metastasis. Here we performed a dose-escalation study of intraperitoneal docetaxel (DTX) combined with S-1 to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer with peritoneal dissemination. Patients and Methods: Twelve gastric cancer patients with positive cytology were enrolled in this study. Peritoneal lavage specimens were obtained under local anesthesia or staging laparoscopy before treatment and the combination chemotherapy was applied in patients with positive cytology. DTX was administered on day 1 intraperitoneally with initial dose of 40 mg/m 2, stepped up to 50 or 60 mg/m2. S-1 was administered at a fixed dose of 80 mg/m2/day on days 1-14, followed by 7 days of rest. After two cycles of the combination chemotherapy, staging laparoscopy was performed to evaluate the effect of the chemotherapy. Simultaneous gastrectomy was performed in cases without peritoneal deposits at staging laparoscopy. Results: The MTD of intraperitoneal DTX was not determined and the RD was defined as 60 mg/m2 because dose-limiting toxicity occurred in only one patient at level II (DTX: 50 mg/m2). Out of twelve patients given the combination chemotherapy, nine had cytologically negative peritoneal lavage and had no peritoneal metastases at surgery after chemotherapy. Conclusion: The combined chemotherapy of S-1 plus intraperitoneal DTX was revealed to be safe and may be effective for gastric cancer with peritoneal dissemination.

Original languageEnglish
Pages (from-to)1335-1339
Number of pages5
JournalAnticancer research
Volume30
Issue number4
Publication statusPublished - Apr 1 2010
Externally publishedYes

Fingerprint

docetaxel
Feasibility Studies
Combination Drug Therapy
Stomach Neoplasms
Laparoscopy
Peritoneal Lavage
Cell Biology
Maximum Tolerated Dose
Drug Therapy
Neoplasm Metastasis
Local Anesthesia
Gastrectomy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Fujiwara, Y., Nishida, T., Takiguchi, S., Nakajima, K., Miyata, H., Yamasaki, M., ... Doki, Y. (2010). Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. Anticancer research, 30(4), 1335-1339.

Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. / Fujiwara, Yoshiyuki; Nishida, Toshiro; Takiguchi, Shuji; Nakajima, Kiyokazu; Miyata, Hiroshi; Yamasaki, Makoto; Yamamoto, Kazuyoshi; Moon, Jeong Ho; Mori, Masaki; Doki, Yuichiro.

In: Anticancer research, Vol. 30, No. 4, 01.04.2010, p. 1335-1339.

Research output: Contribution to journalArticle

Fujiwara, Y, Nishida, T, Takiguchi, S, Nakajima, K, Miyata, H, Yamasaki, M, Yamamoto, K, Moon, JH, Mori, M & Doki, Y 2010, 'Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination', Anticancer research, vol. 30, no. 4, pp. 1335-1339.
Fujiwara Y, Nishida T, Takiguchi S, Nakajima K, Miyata H, Yamasaki M et al. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. Anticancer research. 2010 Apr 1;30(4):1335-1339.
Fujiwara, Yoshiyuki ; Nishida, Toshiro ; Takiguchi, Shuji ; Nakajima, Kiyokazu ; Miyata, Hiroshi ; Yamasaki, Makoto ; Yamamoto, Kazuyoshi ; Moon, Jeong Ho ; Mori, Masaki ; Doki, Yuichiro. / Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. In: Anticancer research. 2010 ; Vol. 30, No. 4. pp. 1335-1339.
@article{f8e1d96cce054d7cbca848c5381f9961,
title = "Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination",
abstract = "Background: Gastric cancer with cancer cells on peritoneal cytology has very poor prognosis because of the existence of simultaneous peritoneal metastasis. Here we performed a dose-escalation study of intraperitoneal docetaxel (DTX) combined with S-1 to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer with peritoneal dissemination. Patients and Methods: Twelve gastric cancer patients with positive cytology were enrolled in this study. Peritoneal lavage specimens were obtained under local anesthesia or staging laparoscopy before treatment and the combination chemotherapy was applied in patients with positive cytology. DTX was administered on day 1 intraperitoneally with initial dose of 40 mg/m 2, stepped up to 50 or 60 mg/m2. S-1 was administered at a fixed dose of 80 mg/m2/day on days 1-14, followed by 7 days of rest. After two cycles of the combination chemotherapy, staging laparoscopy was performed to evaluate the effect of the chemotherapy. Simultaneous gastrectomy was performed in cases without peritoneal deposits at staging laparoscopy. Results: The MTD of intraperitoneal DTX was not determined and the RD was defined as 60 mg/m2 because dose-limiting toxicity occurred in only one patient at level II (DTX: 50 mg/m2). Out of twelve patients given the combination chemotherapy, nine had cytologically negative peritoneal lavage and had no peritoneal metastases at surgery after chemotherapy. Conclusion: The combined chemotherapy of S-1 plus intraperitoneal DTX was revealed to be safe and may be effective for gastric cancer with peritoneal dissemination.",
author = "Yoshiyuki Fujiwara and Toshiro Nishida and Shuji Takiguchi and Kiyokazu Nakajima and Hiroshi Miyata and Makoto Yamasaki and Kazuyoshi Yamamoto and Moon, {Jeong Ho} and Masaki Mori and Yuichiro Doki",
year = "2010",
month = "4",
day = "1",
language = "English",
volume = "30",
pages = "1335--1339",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination

AU - Fujiwara, Yoshiyuki

AU - Nishida, Toshiro

AU - Takiguchi, Shuji

AU - Nakajima, Kiyokazu

AU - Miyata, Hiroshi

AU - Yamasaki, Makoto

AU - Yamamoto, Kazuyoshi

AU - Moon, Jeong Ho

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: Gastric cancer with cancer cells on peritoneal cytology has very poor prognosis because of the existence of simultaneous peritoneal metastasis. Here we performed a dose-escalation study of intraperitoneal docetaxel (DTX) combined with S-1 to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer with peritoneal dissemination. Patients and Methods: Twelve gastric cancer patients with positive cytology were enrolled in this study. Peritoneal lavage specimens were obtained under local anesthesia or staging laparoscopy before treatment and the combination chemotherapy was applied in patients with positive cytology. DTX was administered on day 1 intraperitoneally with initial dose of 40 mg/m 2, stepped up to 50 or 60 mg/m2. S-1 was administered at a fixed dose of 80 mg/m2/day on days 1-14, followed by 7 days of rest. After two cycles of the combination chemotherapy, staging laparoscopy was performed to evaluate the effect of the chemotherapy. Simultaneous gastrectomy was performed in cases without peritoneal deposits at staging laparoscopy. Results: The MTD of intraperitoneal DTX was not determined and the RD was defined as 60 mg/m2 because dose-limiting toxicity occurred in only one patient at level II (DTX: 50 mg/m2). Out of twelve patients given the combination chemotherapy, nine had cytologically negative peritoneal lavage and had no peritoneal metastases at surgery after chemotherapy. Conclusion: The combined chemotherapy of S-1 plus intraperitoneal DTX was revealed to be safe and may be effective for gastric cancer with peritoneal dissemination.

AB - Background: Gastric cancer with cancer cells on peritoneal cytology has very poor prognosis because of the existence of simultaneous peritoneal metastasis. Here we performed a dose-escalation study of intraperitoneal docetaxel (DTX) combined with S-1 to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer with peritoneal dissemination. Patients and Methods: Twelve gastric cancer patients with positive cytology were enrolled in this study. Peritoneal lavage specimens were obtained under local anesthesia or staging laparoscopy before treatment and the combination chemotherapy was applied in patients with positive cytology. DTX was administered on day 1 intraperitoneally with initial dose of 40 mg/m 2, stepped up to 50 or 60 mg/m2. S-1 was administered at a fixed dose of 80 mg/m2/day on days 1-14, followed by 7 days of rest. After two cycles of the combination chemotherapy, staging laparoscopy was performed to evaluate the effect of the chemotherapy. Simultaneous gastrectomy was performed in cases without peritoneal deposits at staging laparoscopy. Results: The MTD of intraperitoneal DTX was not determined and the RD was defined as 60 mg/m2 because dose-limiting toxicity occurred in only one patient at level II (DTX: 50 mg/m2). Out of twelve patients given the combination chemotherapy, nine had cytologically negative peritoneal lavage and had no peritoneal metastases at surgery after chemotherapy. Conclusion: The combined chemotherapy of S-1 plus intraperitoneal DTX was revealed to be safe and may be effective for gastric cancer with peritoneal dissemination.

UR - http://www.scopus.com/inward/record.url?scp=77953787935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953787935&partnerID=8YFLogxK

M3 - Article

C2 - 20530449

AN - SCOPUS:77953787935

VL - 30

SP - 1335

EP - 1339

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -